Jump to content

Scott Shields Emerson

From Wikipedia, the free encyclopedia
Scott Shields Emerson
CitizenshipAmerican
EducationUniversity of Virginia
and University of Washington
OccupationProfessor of biostatistics
TitleEmeritus professor of the University of Washington

Scott Shields Emerson is an American biostatistician and emeritus professor of the University of Washington.[1][2]

Emerson was a professor of biostatistics[3] at the University of Washington in the School of Public Health's department of biostatistics[4] from 1999[5] to 2017.[6][7] Emerson worked on randomized controlled trial design.[8][9] Emerson has been part of advisory committees for the Food and Drug Administration,[10][11] including on work related to Aduhelm.[12][13]

Schooling

[edit]

Emerson studied at the University of Virginia and the University of Washington.

References

[edit]
  1. ^ Joseph, Andrew (June 8, 2021). "Member of FDA's expert panel resigns over controversial Alzheimer's therapy approval".
  2. ^ "Aducanumab Data Finally Published, but Alzheimer's Experts Spot Problems". www.medpagetoday.com. March 23, 2022.
  3. ^ "FDA Committee Expresses Concerns about Promising Alzheimer's Drug". Time.
  4. ^ "Emerson Statistics | R information". www.uwintrostats.org.
  5. ^ Scott Shields Emerson. "Curriculum Vitae" (PDF). emersonstatistics.com.
  6. ^ "Scott S. Emerson, M.D., Ph.D. | Home Page". faculty.washington.edu.
  7. ^ "| UW School of Public Health". sph.washington.edu.
  8. ^ Emerson, Scott S.; Kittelson, John M.; Gillen, Daniel L. (December 10, 2007). "Frequentist evaluation of group sequential clinical trial designs". Statistics in Medicine. 26 (28): 5047–5080. doi:10.1002/sim.2901. PMID 17573678. S2CID 16825572.
  9. ^ "RCTdesign.org : Methods and Software for Clinical Trials". rctdesign.org.
  10. ^ "Advisory Committee Again Urges FDA to Vote No on Aducanumab | ALZFORUM". www.alzforum.org.
  11. ^ Herman, Bob (July 27, 2021). "Biogen pulled Aduhelm paper after JAMA demanded edits". Axios.
  12. ^ "JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy". BioSpace.
  13. ^ Review, The Regulatory (July 6, 2021). "Regulatory Reactivity in FDA's Approval of Aduhelm | The Regulatory Review". www.theregreview.org.